The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Intravascular adenoviral agents in cancer patients: Lessons from clinical trials
Open accessAbstract
A large number of adenoviral agents are being developed for the treatment of cancer. However, the treatment-related death of a patient with ornithine transcarbamylase deficiency following adenovirus administration by hepatic artery has led to serious concerns regarding the safety of intravascular adenovirus. Both replication-incompetent (rAd.p53, e.g., SCH58500) and replication-selective (dl1520, aka Onyx-015; CG7870) oncolytic adenoviruses, by intravascular administration, are in clinical trials. We review Phases I and I/II results from these clinical trials. dl1520 and rAd.p53 were well-tolerated following hepatic artery infusion at doses of up to 2×1012 and 2.5×1013 particles, respectively. At a dose of 7.5×1013 particles, rAd.p53 was associated with dose-limiting cardiac output suppression; dl1520 dose escalation did not proceed higher than 2×1012. Intravenous (i.v.) infusions of dl1520 and CG7870 have been well tolerated by i.v. infusion at doses of 2×1013 and 6×1012, respectively, without identification of a maximally tolerated dose to date. Mild/moderate transaminitis was demonstrated in some patients on both the hepatic arterial and i.v. trials at doses ≥1012 particles. Interleukin (IL)-6 and IL-10 were induced in a dose-dependent manner in most patients, but significant interpatient and intrapatient (on repeat doses) variabilities were demonstrated. Evidence of p53 gene expression (Ad.p53) or viral replication (dl1520) was demonstrated in the majority of patients receiving ≥1012 particles. Over 100 cancer patients have been treated with intravascular adenovirus constructs to date with an acceptable toxicity profile; further clinical trial testing appears appropriate in cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
Self-citationKhuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., et al. (2000) · Nature Medicine · doi:10.1038/78638 · Cited by 1,101
Self-citationHeise, C., Sampson-Johannes, A., Williams, A., Mccormick, F., Von Hoff, D. D., & Kirn, D. H. (1997) · Nature Medicine · doi:10.1038/nm0697-639 · Cited by 940
Self-citationAttenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas
Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., & Martuza, R. L. (1995) · Nature Medicine · doi:10.1038/nm0995-938 · Cited by 822
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
Fueyo, J., Gomez-Manzano, C., Alemany, R., Lee, P. S., McDonnell, T. J., Mitlianga, P., Shi, Y.-X., Levin, V. A., Yung, W. K. A., & Kyritsis, A. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203251 · Cited by 764
Gene Therapy Death Prompts Review of Adenovirus Vector
Marshall, E. (1999) · Science · doi:10.1126/science.286.5448.2244 · Cited by 760
Reovirus Therapy of Tumors with Activated Ras Pathway
Coffey, M. C., Strong, J. E., Forsyth, P. A., & Lee, P. W. K. (1998) · Science · doi:10.1126/science.282.5392.1332 · Cited by 750
Gene Therapy for Cancer: What Have We Done and Where Are We Going?
Roth, J. A., & Cristiano, R. J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.1.21 · Cited by 635
Rodríguez, R., Schuur, E. R., Lim, H. Y., Henderson, G. A., Simons, J. W., & Henderson, D. (1997) · PubMed · Cited by 584
An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
Heise, C., Hermiston, T., Johnson, L., Brooks, G., Sampson-Johannes, A., Williams, A., Hawkins, L., & Kirn, D. (2000) · Nature Medicine · doi:10.1038/80474 · Cited by 583
Self-citation
Cited by
Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691
Adenovirus vectors for gene therapy, vaccination and cancer gene therapy
Wold, W., & Toth, K. (2014) · Current Gene Therapy · doi:10.2174/1566523213666131125095046 · Cited by 555
Recent progress in the battle between oncolytic viruses and tumours
Parato, K. A., Senger, D., Forsyth, P. A. J., & Bell, J. C. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1750 · Cited by 536
Polymeric Growth Factor Delivery Strategies for Tissue Engineering
Chen, R. R., & Mooney, D. J. (2003) · Pharmaceutical Research · doi:10.1023/a:1025034925152 · Cited by 435
WADIA, J., & DOWDY, S. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.10.005 · Cited by 428
Metadata
- Authors
- Reid, T., Warren, R., & Kirn, D.
- Venue
- Cancer Gene Therapy
- Published
- 2002-11-22
- Volume
- 9
- Issue
- 12
- Pages
- 979-986
- ISSN
- 0929-1903 (ISSN-L)
- 1476-5500
- OpenAlex
- W1972359936
- Cited by
- 258
- References
- 37
- FWCI
- 10.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intravascular adenoviral agents in cancer patients: Lessons from clinical trials. https://app.cochat.ai/papers/10.1038/sj.cgt.7700539
- The paper
- Reid, T., Warren, R., & Kirn, D. (2002). Intravascular adenoviral agents in cancer patients: Lessons from clinical trials. Cancer Gene Therapy. https://doi.org/10.1038/sj.cgt.7700539
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.